I'm as cautious as you are Ramses.
NPAT of $24.3M from revenue of $3.186B is so thin (<1%) in a market where highly leveraged shopping centre pharmacies are taking large PBS profit hits. I agree that it also seems that they may have been made to bring some contingent liabilities to book.
You also mentioned Amex. I recall that some years ago I heard that API would guarantee any pharmacists Amex spending (recollection, not factual assertion). My wife sold her shopping centre pharmacy a few years ago (wasn't an API branded one) & we hold no API stock.
Caution as you say (no recommendation; DYOR).
- Forums
- ASX - By Stock
- is there anyone
I'm as cautious as you are Ramses.NPAT of $24.3M from revenue of...
-
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add API (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online